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Introduction
Human cancers are characterized by recurrent somatic copy 
number alterations (SCNAs), which include both focal and 
broad arm-level amplifications and deletions (1). How these 
alterations contribute to tumorigenesis remains a central ques-
tion in cancer research. Specifically, large heterozygous dele-
tions are thought to produce a “second hit” toward the inac-
tivation of a tumor suppressor gene (TSG), hence fulfilling 
Knudson’s two-hit hypothesis (2). However, TSGs that fulfill 
this paradigm are often not identified in chromosomal loci dis-
playing consistent loss of heterozygosity (LOH) (1, 3), calling 
into question whether bona fide TSGs actually reside in those 
regions. One possible explanation is that these deletions arise 
from genomic instability and are inconsequential to tumor for-
mation, but another plausible explanation is that haploinsuffi-
ciency of 2 or more TSGs in the deleted regions cooperates to 
promote tumorigenesis (4–9).
Large deletions of chromosome 8p are common in a variety 
of tumor types, including breast, colon, liver, and lung cancer and 
leukemia (9–12). A region of 8p loss, spanning cytobands 8p12–
8p23, is frequently observed in human lung adenocarcinoma (11, 
13), and multiple putative TSGs have been proposed in this region 
(9, 13, 14). Using a knockout mouse model, we previously identi-
fied the 8p21 gene DOK2, encoding an adaptor protein that mod-
ulates the RAS/RTK signaling pathway, as a human lung tumor 
suppressor (14). Human genetics and in vitro functional data have 
also identified DUSP4, encoding a dual-specificity phosphatase 
that functions as part of a negative feedback loop to terminate the 
activity of MAPKs, as another candidate lung TSG on 8p (11). Nota-
bly, deletions of 8p in human lung adenocarcinoma frequently 
encompass both DOK2 and DUSP4, and are enriched in tumors 
with EGFR mutations (11, 15).
Given the genomic localization of DOK2 and DUSP4 and 
their convergent function in suppression of MAPK signaling, 
we hypothesized that compound haploinsufficiency of DOK2 
and DUSP4 promotes lung tumorigenesis. Here we show that 
although heterozygous or complete loss of Dusp4 is not suffi-
cient to initiate lung tumorigenesis in mice, heterozygous loss 
of Dusp4 markedly accelerates lung tumorigenesis in Dok2- 
heterozygous mice. In agreement with these findings, we find 
that concomitant downregulation of DOK2 and DUSP4 is associ-
ated with poor survival in human lung adenocarcinoma.
Results
Dusp4 and Dok2 heterozygosity cooperate to promote lung tumori-
genesis in vivo. Human genetics and in vitro functional studies pre-
viously identified DUSP4 as a putative 8p12 TSG in human lung 
adenocarcinoma (11). To study the impact of Dusp4 loss on lung 
tumorigenesis in mice, we analyzed Dusp4-KO mice generated by 
a targeted deletion strategy (16). Unlike Dok2 mutant mice (14), 
Dusp4+/− and Dusp4−/− mice did not develop lung cancer within a 
12- or 18-month follow-up (Figure 1, A and B, and Table 1), indi-
cating that loss of Dusp4 alone in mice is not sufficient to initiate 
lung tumorigenesis in vivo.
Recurrent broad-scale heterozygous deletions are frequently observed in human cancer. Here we tested the hypothesis that 
compound haploinsufficiency of neighboring genes at chromosome 8p promotes tumorigenesis. By targeting the mouse 
orthologs of human DOK2 and DUSP4 genes, which were co-deleted in approximately half of human lung adenocarcinomas, we 
found that compound-heterozygous deletion of Dok2 and Dusp4 in mice resulted in lung tumorigenesis with short latency and 
high incidence, and that their co-deletion synergistically activated MAPK signaling and promoted cell proliferation. Conversely, 
restoration of DOK2 and DUSP4 in lung cancer cells suppressed MAPK activation and cell proliferation. Importantly, in contrast 
to downregulation of DOK2 or DUSP4 alone, concomitant downregulation of DOK2 and DUSP4 was associated with poor 
survival in human lung adenocarcinoma. Therefore, our findings lend in vivo experimental support to the notion that compound 
haploinsufficiency, due to broad-scale chromosome deletions, constitutes a driving force in tumorigenesis.
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Dok2+/− Dusp4+/− mice were adenocarcinomas with solid and pap-
illary growth patterns (Supplemental Figure 1B), similar to lung 
tumors in Dok-mutant mice (14). However, they had a significantly 
elevated frequency of mitotic cells positive for Ki-67 staining 
when compared with Dok2+/− lung tumors (Figure 2B). Given the 
role of DOK2 and DUSP4 in the regulation of RTK signaling, we 
conducted IHC to determine the levels of phosphorylated MAPK/
Erk in the murine tumors. Dok2+/− lung tumors showed moderate 
staining for phosphorylated Erk (Figure 2C), while Dok2+/− Dusp4+/− 
lung tumors showed stronger staining for phosphorylated Erk than 
Dok2+/− lung tumors (Figure 2C), which was confirmed by West-
ern blot analysis (Figure 2D). In contrast, lung tissues from WT 
and Dusp4-mutant mice showed low or undetectable staining for 
Ki-67 and phosphorylated Erk (Supplemental Figure 1C). Thus, in 
contrast to heterozygous loss of Dok2, heterozygous loss of Dusp4 
did not initiate lung tumorigenesis, but instead accelerated the 
progression of tumors initiated by Dok2 heterozygosity, possibly 
through augmentation of MAPK activation.
Importantly, IHC staining showed that protein expression 
of both Dok2 and Dusp4 was retained in the Dok2+/− Dusp4+/− 
lung tumors, indicating that complete genetic loss of either Dok2 
or Dusp4 is not required for tumor development (Figure 2E). 
We previously identified DOK2 as a candidate human lung 
TSG (14). 30% of Dok2 heterozygous (Dok2+/−) mice develop lung 
adenocarcinoma, albeit with a long latency of 15–19 months. 
Tumors from these mice do not lose the WT Dok2 allele, sug-
gesting that Dok2 is a haploinsufficient TSG. Thus, we sought 
to determine whether haploinsufficiency of Dusp4 impacts lung 
tumorigenesis initiated by Dok2 haploinsufficiency in vivo. We 
crossed the Dusp4+/− mice with Dok2+/− mice to generate mice 
compound-heterozygous for Dok2 and Dusp4 (Dok2+/− Dusp4+/− 
mice) and compared the incidence of lung adenocarcinoma in 
single- and compound-mutant mice at 12 and 18 months of age. 
At 12 months, Dok2+/− Dusp4+/− mice were the only genotype of 
mice that developed lung adenocarcinoma at moderate (21%) 
penetrance (Figure 1A and Table 1). Further examination of 
lungs of the younger Dok2+/− Dusp4+/− mice revealed that as early 
as 9 months of age, 20% of Dok2+/− Dusp4+/− mice developed 
lung tumors (Supplemental Figure 1A, n = 10). At 18 months, 
an analysis of 157 mice showed that Dok2+/− Dusp4+/− mice had 
a significantly higher incidence of lung adenocarcinoma than 
Dok2+/− mice (Figure 1B and Table 1).
Compared with Dok2+/− lungs, Dok2+/− Dusp4+/− lungs con-
tained significantly larger tumor nodules (Figure 2A). Tumors in 
Table 1. Incidence of lung adenocarcinoma in cohorts of WT, Dok2-, Dusp4-, and compound-mutant mice
Age of mice
12 months 18 months
Genotype ncancer ntotal % with cancer P versus 
Dok2+/– Dusp4+/– A
ncancer ntotal % with cancer P versus Dok2
+/– 
Dusp4+/– A
WT 0 21 0 0.031 1 25 4% <0.001
Dusp4+/– 0 22 0 0.028 0 24 0 <0.001
Dusp4–/– 0 29 0 0.010 0 24 0 <0.001
Dok2+/– 0 23 0 0.027 7 26 27% 0.032
Dok2+/– Dusp4+/– 6 28 21% – 17 30 57% –
Dok2–/– 0 24 0 0.025 14 28 50% 0.793
AThe incidence of lung adenocarcinoma in Dok2 and Dusp4 mutant mice at 12 and 18 months of age, respectively, was compared with that of compound 
Dok2 and Dusp4 heterozygous mice using Fisher’s exact test; P < 0.05 was considered significant.
Figure 1. Compound heterozygous loss of Dok2 and Dusp4 in mice induces lung cancer. (A and B) Lung adenocarcinoma incidence in Dusp4 and Dok2 
heterozygous-, homozygous-, and compound heterozygous-KO mice at 12 months of age (A) and at 18 months of age (B). Mouse numbers and statistics 
are summarized in Table 1.
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or/and DUSP4 in 3 lung cancer cell lines, H1650, H1975, and 
H3255, all characterized by EGFR mutation and loss of one copy of 
DOK2 and DUSP4 (Supplemental Table 1; data from Cancer Cell 
Line Encyclopedia hosted on cBioPortal) (17). Overexpression of 
either DOK2 or DUSP4 significantly suppressed MAPK activation, 
Therefore, Dok2 and Dusp4 are haploinsufficient in their tumor- 
suppressive function and their ability to suppress MAPK activation.
DOK2 and DUSP4 cooperate to suppress MAPK activation and 
cell proliferation. To assess the tumor-suppressive role of DOK2 
and DUSP4 in human lung cancer, we stably overexpressed DOK2 
Figure 2. Histopathology of lung tumors in Dok2+/− and Dok2+/−Dusp4+/− mice. (A) Gross view of the 5 lung lobes from a representative Dok2+/− and Dok2+/− 
Dusp4+/− mouse. Arrowheads indicate tumor nodules. Quantification of the size of tumors was carried out with ImageJ software (n = 5 mice per genotype). 
Scale bars: 2 mm. (B) IHC and quantification of Ki-67 staining in lung tumors from age-matched Dok2+/− and Dok2+/− Dusp4+/− mice (n = 3 mice per genotype). 
Scale bars: 50 μm. (C) IHC of phosphorylated Erk in lung tumors from age-matched Dok2+/− and Dok2+/− Dusp4+/− mice (n = 3 mice per genotype). Scale bars: 
50 μm. (D) Western blot analysis of lung lysates from 9-month-old WT, Dusp4+/−, Dok2+/−, and Dok2+/− Dusp4+/− mice. Numbers indicate the ratios relative to 
controls for phospho-protein/total protein. (E) Serial sections of lung tissue stained with H&E and IHC for Dok2 and Dusp4 from an 18-month-old WT and 
Dok2+/− Dusp4+/− mouse. Scale bars: 50 μm. In A and B, data are shown as mean ± SEM. Student’s t test (2 tailed) was used to determine significance.
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and DUSP4 converge on the suppression of MAPK signaling led 
us to investigate whether cells with one copy loss of DOK2 and 
DUSP4 might exhibit enhanced sensitivity to MEK inhibition 
compared with cells with intact copies of DOK2 and DUSP4. To 
avoid confounding effects of MAPK activity induced by mutant 
EGFR or KRAS, we examined the response to MEK inhibition in 
cells with WT EGFR and KRAS with either one copy loss of DOK2 
and DUSP4 (ChagoK1 and H1299) or no loss of DOK2 and DUSP4 
(H1648) (Supplemental Table 1). We found that both ChagoK1 
and H1299 cells exhibited higher ERK activation and were more 
sensitive to MEK inhibition than H1648 cells (Figure 3G). These 
and combined expression of DOK2 and DUSP4 suppressed MAPK 
to the greatest degree in H1650 and H3255 cell lines (Figure 3, 
A–C). Consistent with these findings, in a growth curve assay, cells 
expressing either DOK2 or DUSP4 displayed an impaired growth 
rate compared with cells transfected with empty vector (Figure 3, 
D–F). Combined expression of DOK2 and DUSP4 further impaired 
cell growth compared with either DOK2 or DUSP4 overexpression 
(Figure 3, D–F). These data further support a cooperative role of 
DOK2 and DUSP4 in lung tumor suppression.
Compound heterozygosity of DOK2 and DUSP4 confers 
enhanced sensitivity to MEK inhibition. The observation that DOK2 
Figure 3. DOK2 and DUSP4 cooperate to suppress lung cancer cell proliferation in vitro. (A–C) Western blot of cell lysates from lung cancer cell lines 
H1650 (A), H1975 (B), and H3255 (C) stably expressing vector, DOK2, or/and DUSP4. Quantification of p-ERK/ERK levels was carried out with ImageJ soft-
ware (n = 3 experiments). Numbers indicate the ratios relative to controls for phosphoprotein/total protein. Data are shown as mean ± SEM. Student’s t 
test (2 tailed) was used to determine significance. (D–F) Growth curve analysis of lung cancer cell lines H1650 (D), H1975 (E), and H3255 (F) stably express-
ing vector, DOK2, or/and DUSP4. Relative cell number was determined after cell fixation and crystal violet staining using OD at 595 nm. Data were normal-
ized against the OD value on day 1 of each cell line. Data are shown as mean ± SD of a representative experiment (n = 3 experiments). Two-way ANOVA 
with Bonferroni’s post hoc test was used to determine significance. (G) Growth curve analysis of lung cancer cell lines ChagoK1, H1299, and H1648 treated 
with various doses of the MEK inhibitor U0126 for 7 days. Relative cell number was determined after cell fixation and crystal violet staining using OD at 
595 nm. Western blot analysis indicated the expression of p-ERK. Data were normalized against the OD value of vehicle-treated cells. Data are shown as 
mean ± SEM of a representative experiment (n = 3 experiments). Two-way ANOVA with Bonferroni’s post hoc tests were used to determine significance.
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in 49% of cases, and compound-heterozygous loss of DOK2 and 
DUSP4 accounted for 90% of these co-deletion cases (Figure 4B). 
Copy number loss of DOK2 or DUSP4 was correlated with low 
expression of their respective mRNAs (Supplemental Figure 2B), 
suggesting that copy number alterations deregulate the level of 
DOK2 and DUSP4 in lung adenocarcinoma.
To evaluate DOK2 and DUSP4 protein expression in human 
lung tumors, we performed tissue microarray (TMA) analysis in 
57 lung tumors (Supplemental Table 2). DOK2 expression was at 
a low or undetectable level in the majority of tumor samples (Sup-
data suggest that compound haploinsufficiency might serve as a 
biomarker to predict responsiveness to anticancer therapies.
Compound loss of DOK2 and DUSP4 predicts poor survival in 
human lung adenocarcinoma. To assess the relevance of these find-
ings to human lung adenocarcinoma, we analyzed copy number 
of DOK2 and DUSP4 in 513 human lung adenocarcinoma samples 
from The Cancer Genome Atlas (TCGA). Copy number loss of 
DOK2 and DUSP4 was observed in 52% and 50% of cases, respec-
tively, the majority of which were single copy losses (Figure 4A and 
Supplemental Figure 2A). Co-loss of DOK2 and DUSP4 occurred 
Figure 4. Compound loss of DOK2 
and DUSP4 expression and its clin-
ical implication in human lung ade-
nocarcinomas. (A and B) Percentage 
of tumors with deletion of DOK2  
or DUSP4 (A) and co-deletion of 
DOK2 and DUSP4 (B) in the TCGA 
dataset. (C) DUSP4 protein expres-
sion in a TMA of normal lung tissue 
or lung cancer samples. P values 
were determined by 2-tailed t tests. 
Data are shown as mean ± SD. (D) 
Representative imagines of IHC 
staining for DOK2 and DUSP4 protein 
from normal lung tissue or 2 pairs 
of tumor samples with moderate or 
low expression of DOK2 and DUSP4 
protein. Arrows indicate positive 
staining of DOK2 or DUSP4 protein  
in lung epithelial cells. Scale bars:  
50 μm. (E) Kaplan-Meier survival 
curve of lung adenocarcinoma 
patients stratified by DOK2 and 
DUSP4 expression. P values were 
determined by log-rank test. (F) 
Models of compound haploinsuffi-
ciency of DUSP4 and DOK2 promot-
ing lung tumorigenesis. DSUP4- 
heterozygous cells: The activation of 
RTK signaling is tightly controlled by 
a negative feedback loop involving 
the recruitment of DOK2 and RASA1. 
The remaining WT DUSP4 allele 
is sufficient to suppress the low 
level of ERK activity transduced by 
RTK signaling. DUSP4 and DOK2 
compound-heterozygous cells: 
Loss of DOK2 results in decreased 
recruitment of RASA1, allowing 
enhanced RTK and downstream ERK 
activation. The remaining WT DUSP4 
allele is insufficient to suppress the 
high level of ERK activity and leads 
to increased lung tumorigenesis. 
White rectangles indicate genomic 
deletions; gray text indicates low 
expression of proteins of interest.
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plemental Table 2). Likewise, DUSP4 protein expression was sig-
nificantly lower in tumor tissue compared with the noninvolved 
normal lung (Figure 4C and Supplemental Table 2). Tumors with 
low expression of both DOK2 and DUSP4 protein accounted for 
63% (34 of 54) of tumor samples examined (Supplemental Table 2 
and Figure 4D).
To determine whether compound loss of DOK2 and DUSP4 
impacts clinical outcome, we analyzed whether downregulation of 
DOK2 and DUSP4 is associated with survival outcome in human 
lung adenocarcinoma. We analyzed gene expression data from 764 
lung cancer patients with available survival data (18–22). We found 
that although low expression of either DOK2 or DUSP4 alone had 
no association with survival outcome (Figure 4E), concomitant 
low expression of DOK2 and DUSP4 was significantly associated 
with poor survival (Figure 4E). Thus, compound loss of DOK2 and 
DUSP4 may be a predictor of aggressive disease in human lung 
cancer. Consistent with these findings, the association between 
copy number loss of DOK2 or DUSP4 alone and patient survival 
only approached significance (Supplemental Figure 2C). Taken 
together, these data indicate that concomitant downregulation of 
DOK2 and DUSP4 promotes lung tumorigenesis.
Discussion
Our study provides direct evidence for a model in which compound 
haploinsufficiency contributes to tumor progression as a result of 
heterozygous chromosomal deletions (Figure 4F). We found that 
in mice, loss of Dusp4 alone is insufficient to initiate cancer in the 
lung, which could be due to the redundancy in the Dusp protein 
family. However, heterozygous loss of Dusp4 did accelerate the 
onset and incidence of lung adenocarcinoma initiated by Dok2 
heterozygosity. This work highlights the utility of mouse mod-
els and functional assays in disentangling the genetic effects of 
SCNAs. Future efforts should be therefore directed toward defin-
ing the combinatorial genetic interactions in recurrent cancer- 
associated somatic alterations, facilitated by TALEN or CRISPR/
Cas9 technology that can now inactivate multiple genes simulta-
neously in heterozygosity (8, 23).
This study lends further support to the notion that recurrent 
broad-scale deletions in human cancer, including 3p, 5q, 8p 9p, and 
17p (1), play a critical role in tumorigenesis. Our work adds to a body 
of evidence supporting our hypothesis that loss of one allele, or 
reduced expression, of a critical TSG is functionally important either 
intrinsically or in combination with mutation of other genes (4, 5, 24).
Our results demonstrate that compound haploinsufficiency can 
lead to activation of the convergent pathway and confer enhanced 
sensitivity to drugs inhibiting the aberrantly activated pathway. 
While much work is needed to translate the therapeutic implications 
of compound haploinsufficiency to the clinic, the high frequency of 
these genomic events in human cancer warrants further investiga-
tion. Finally, as it is a recently identified lung TSG, the genetic interac-
tions of DOK2 with its various effectors, including RASA1/RASGAP 
(Figure 4F), should be further explored. For instance, loss or muta-
tion of RASA1 is observed in 2% of lung adenocarcinoma, which 
would be predicted to disrupt DOK2’s ability to suppress MAPK 
signaling, hence defining a novel subtype of lung cancer that is 
highly sensitive to MEK inhibition (25). Therefore, understand-
ing the relationship between 8p genes and their effectors might 
also help facilitate patient stratification and the development of 
more effective cancer treatments.
Methods
Mice and histopathological analyses. All mouse strains have been pre-
viously described (16, 26). Dusp4-KO mice originally generated in a 
mixed C57BL/6 and 129/Sv genetic background were backcrossed 
to a 129/Sv background by successive mating of Dusp4-heterozygous 
male mice to 129/Sv female mice and then maintained on a 129/Sv 
background as Dok2-KO mice. Total body necropsy and histopatho-
logical analyses were performed on cohorts of male and female mice 
at 9, 12, and 18 months of age. Mouse tissues were fixed in 4% para-
formaldehyde, embedded in paraffin, and sectioned and stained with 
H&E for pathological analyses.
Cell lines, Western blotting, and immunohistochemistry. All cell lines 
were obtained from ATCC and checked for mycoplasma by use of a 
MycoAlert Mycoplasma Detection Kit (Lonza). Cells and tissues were 
lysed with RIPA buffer (50 mM Tris [pH8], 150 mM NaCl, 0.1% SDS, 
0.5% sodium deoxycholate, 1% NP40, 1 mM EDTA, and protease and 
phosphatase inhibitor cocktail [Roche]). For Western blotting, the 
following antibodies were used. Anti–phospho-ERK (catalog 9101) 
and anti-ERK (catalog 9102) were from Cell Signaling Technology. 
Anti-DUSP4 (S-18) and anti-HSP90 (H-114) were from Santa Cruz 
Biotechnology. Anti–β-actin (A3853) was from Sigma-Aldrich. Densi-
tometry quantification was performed with NIH ImageJ. For immuno-
histochemistry, anti–phospho-ERK (20G11) was from Cell Signaling 
Technology. Anti–Ki-67 (SP6) was from Thermo Fisher Scientific. 
Anti-DUSP4 (10739-1-AP) was from Proteintech. Anti-DOK2 for both 
applications was provided by B. Clarkson (Memorial Sloan Ketter-
ing Cancer Center, Molecular Pharmacology and Chemistry Pro-
gram, New York, New York, USA). See complete unedited blots in the 
supplemental material.
Generation of lung cancer cell lines stably overexpressing DOK2 or/and 
DUSP4, and cell growth analysis. Retrovirus was generated by transfec-
tion of pCL-Ampho and pBabe-puro-DOK2 or pBabe-hygro-DUSP4 
into 293T cells. Forty-eight and 72 hours after transfection, culture 
supernatants were filtered, supplemented with Polybrene, and added 
to lung cancer cell lines. Forty-eight hours after the last infection, cells 
were selected for 2 days in media containing 2 μg/ml puromycin or 
100 μg/ml hygromycin before use in experiments. For growth curve 
analysis, 1.5 × 104 cells per well were plated into 12-well plates. At the 
indicated times, cells were washed with PBS, fixed in 10% formalin, 
and rinsed with distilled water. Cells were stained with 0.1% crystal 
violet, rinsed extensively, and dried. Cell-associated dye was extracted 
with 1.0 ml of 10% acetic acid and then diluted, and the optical den-
sity (OD) at 595 nm was determined. Within an experiment, each 
point was determined in triplicate. The growth curve experiment was 
repeated 3 times.
TMA analysis. Sections of formalin-fixed, paraffin-embedded 
lung surgical specimens from 57 patients with lung cancer were stained 
with H&E and reviewed to identify viable, morphologically represen-
tative areas of normal lung and tumor areas from which needle core 
samples were taken. From each specimen, triplicate tissue cores with 
diameters of 1 mm were punched and arrayed onto a recipient paraf-
fin block using a precision instrument (Beecher Instruments). Five- 
micrometer sections of these TMA blocks were stained with H&E for 
morphology assessment and further used for IHC analysis.
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Study approval. Mouse studies were approved by the BIDMC 
IACUC under protocol 082-2014. The TMA used in this study was 
constructed at the Icahn School of Medicine at Mount Sinai following 
an IRB-approved protocol. Written informed consent was obtained 
from patients for use of pathologic tissue.
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Copy number, gene expression, and survival analysis. For the copy 
number variation analysis, we downloaded data from the TCGA 
database. The cutoff thresholds we used were −0.3 for deletions 
and 0.6 for amplifications; those lower than −0.8 were considered 
as homozygous deletions and higher than 0.8 as 2-copy amplifi-
cations. GISTIC (Genomic Identification of Significant Targets 
in Cancer) analysis was conducted to identify the copy number 
alterations of the chromosome 8p genomic region in TCGA lung 
adenocarcinoma samples. Deletion of many regions of chromo-
some 8p was detected across TCGA lung adenocarcinoma samples. 
The estimated FDR (q values) for chromosome 8p deletion was 
drawn along the chromosome coordinates (27). A t test was used 
to compare mRNA expression of DOK2 or DUSP4 against its copy 
number change among the homozygous, heterozygous, and no- 
alteration groups. For the gene expression and survival analysis of 
human samples, we collected lung cancer microarray raw datasets 
from the NCBI GEO, including GSE31210, GSE37745, GSE19188, 
GSE29013, and GSE3141. All of these data were from the Affymetrix 
U133 plus 2.0 platform. We conducted gene expression data nor-
malization together. Patient samples were ranked by the expression 
of the DOK2 gene from low to high. The first one-third of patients 
were considered as DOK2-low, the last one-third were considered 
as DOK2-high. A similar classification of patient samples was con-
ducted for the DUSP4 gene. The “co-low” group (n = 96 samples) 
was derived from the overlap of DOK2-low (n = 164 samples) and 
DUSP4-low (n = 164); the “co-high” group (n = 65 samples) from 
overlap of DOK2-high and DUSP4-high. Survival analysis was con-
ducted with the CRAN R packages “survminer” and “survival.” 
We performed pairwise comparisons in survival analysis among 4 
groups, with corrections for multiple testing.
Statistics. For analysis of continuous data, datasets were compared 
using unpaired 2-tailed Student’s t tests. For analysis of categorical data 
(for example, cancer incidence), 2 × 2 contingency tables were con-
structed, and datasets were compared using Fisher’s exact test. For anal-
ysis of cell growth data, datasets were compared using 2-way ANOVA 
with Bonferroni’s post hoc tests. P values less than 0.05 were considered 
statistically significant. All statistical tests were executed using Graph-
Pad Prism software or the statistical software R (version 3.1.2).
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